Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy

Rationale: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted (177)Lu radioligand therapy in metastatic castration-resistant prostate carcinoma (mCRPC), some patients do not respond and other patients with initially good response develop resistance to this treatment....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Theranostics
Auteurs principaux: Rosar, Florian, Hau, Fabian, Bartholomä, Mark, Maus, Stephan, Stemler, Tobias, Linxweiler, Johannes, Ezziddin, Samer, Khreish, Fadi
Format: Artigo
Langue:Inglês
Publié: Ivyspring International Publisher 2021
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7977444/
https://ncbi.nlm.nih.gov/pubmed/33754047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.56211
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires